MeowXin Magnetic Submits IPO Prospectus: China's First TITIAN Atrial Fibrillation Ablation Robot

According to the National Bureau of Statistics, there were approximately 12 million patients with atrial fibrillation (AF) in China in 2020. AF is closely associated with age, with prevalence increasing as age advances. The age-standardized prevalence of AF among adults aged 45 years and older in China is approximately 2%. Statistics show that the prevalence reaches 5% for both men and women in the population aged 75 years and older. By the end of 2024, ChinaAged 65 and aboveThe population will reach approximately240 million people, among which the consultation rate for atrial fibrillation indications willUp to 42%Atrial fibrillation has become a major cardiovascular disease threatening human health.

AsChina Leads in Cardiac Interventional Robotics TechnologyEnterpriseSince its establishment in 2018, Shaoxing Mayo Cardio-Magnetic Medical Technology Co., Ltd. (hereinafter referred to as “Mayo Cardio-Magnetic”) has been driven by clinical needs to innovate, dedicating itself to the development of atrial fibrillation surgical robots. These systems not only enhance the precision and stability of surgical maneuvers but also improve procedural safety through sub-millimeter navigation accuracy. Furthermore, the company is developing remote surgical systems to significantly reduce physicians’ exposure to X-ray radiation during procedures. In collaboration with clinicians from top-tier cardiac intervention centers, Mayo Cardio-Magnetic is committed to standardizing technical operations for atrial fibrillation procedures, shortening the learning curve for physician training, addressing the shortage of medical professionals, and increasing the treatment penetration rate of atrial fibrillation surgeries in China.

TITIAN Titian® Atrial Fibrillation Surgical RobotCurrently, it isChina’s first and the world’s only electrophysiology interventional surgical robot compatible with mainstream catheter sheaths,Approved for inclusion in the NMPA’s Special Approval Procedure for Innovative Medical Devices in April 2023. On January 26, 2024, Mayo Heart Magnetics’ first innovative device product, the TITIAN® Atrial Fibrillation Surgical RobotSuccessfully Completed Enrollment for the Final Pre-Marketing Registration Clinical Trial!This milestone marks the official launch of pre-market registration filings for China’s first domestically produced cardiac interventional surgery robot, bringing it one step closer to clinical use!

May 15 (Wednesday) at 19:30, VCBeat Select New Product Review No. 59 invitesChen Yuemeng, Founder & CEO of Mayo Heart Magnetism、Li Guangsong, Co-founder of Mayo Heart Magnetism、Liu Ming, Director of the Clinical Training Department for Cardiovascular Magnetism at Mayo Clinic、Zhu Xiaoyan, Sales Director for East China at Mayo Heart Magnetism, presenting the innovative medical device TITIAN Titian® Atrial Fibrillation Surgical Robot.

Rapid learning curve; sheath-and-catheter integrated surgical robot with superior 3D manipulation precision and stability

01. Transmission Component of the Control System for Single-Use Electrophysiology Interventional Devices: EP FLORA®

02. Physician Controller & Workstation Computer 

Precise Quantitative Control of Catheters and Sheaths

Intraoperative Real-Time Graphical Sheath Relationship

Achieve Millimeter-Level Precise and Stable Control of Catheters and Sheaths in Electrophysiology Procedures

Remote Dual-Robotic-Arm-Guided Ablation Surgery

Reducing Radiation Injury from X-ray Fluoroscopy

Compatible with mainstream ablation catheters and introducer sheaths, conforming to clinical usage practices.

Scan the QR code on the poster to add our assistant and reserve your spot for the live stream.

Chen Yuemeng, Founder and CEO of Mayo Heart & Magnetism

National “Ten Thousand Talents Program” Leading S&T Expert, Shanghai Municipal Party Committee Organization Department “Thousand Talents Program” Expert, Zhejiang Provincial “Talent Introduction Program” Expert, and Leader of a Zhejiang Provincial Pioneer Entrepreneurial Team.

Held a total of 82 granted patents in China and the United States, and published 12 papers as the first author in IEEE scientific journals and at global technology conferences.

Li Guangsong, Co-founder of Mayo Cardio-Magnetic

With years of supply chain management experience at well-known multinational corporations and group companies, currently responsible for clinical affairs, marketing, and sales.

Liu Ming, Director of the Clinical Training Department for Cardiovascular Magnetism at Mayo Clinic

Former Senior Electrophysiology Training Technical Specialist at Johnson & Johnson and Philips

Zhu Xiaoyan, Sales Director, East China Region, Mayo Clinic Magnetoencephalography

22 years of experience in product sales and registration at renowned domestic and international medical device/equipment companies.

Mayo XinCi was established in 2018 as a medical technology company specializing in the core R&D of navigation technologies for interventional cardiology procedures and devices for cardiac interventions. The team integrates the combined strengths of clinical practice, education, research, and enterprise, possessing comprehensive capabilities in academia, scientific research, operations, and market expansion. Headquartered in Shaoxing, Zhejiang Province, the company has established core R&D centers in Shanghai, Hangzhou, and Shaoxing.

Holding 60 granted patents across various categories, with 61 invention patents under substantive examination and 11 patent applications officially accepted. Awarded First Prize in the National Finals of the Biomedical Track at the 2020 China Innovation & Entrepreneurship Competition, and First Prize in the National Finals of the 2021 China Medical Device Innovation & Entrepreneurship Competition.

The company boasts an authoritative team of clinical cardiologists with over 30 years of experience in interventional procedures, a digital signal processing team with annual production capabilities in the tens of millions for satellite navigation chips, and an industrial team specializing in core electromagnetic and motor control technologies. Through the relentless efforts of these interdisciplinary teams, Mayo Magnetics has developed multiple product lines of cardiac surgical robots, including the TITIAN® Cardiac Electrophysiology Surgical Robot, the Mantai® Green Electrophysiology Surgical Robot System, and the RAPHAELLO® Flexible Magnetic Navigation System for Cardiac Interventional Procedures.

Mayo Heart Magnetism is committed to becoming a leader in cardiac interventional surgical robots, developing revolutionary intelligent catheterization laboratory surgical solutions for the 70 million arrhythmia patients in our country, and extending healthy lives.

“Artery Select New Product Launch” is a live-streaming program under the “Artery Select” brand, dedicated to supporting medical enterprises in launching innovative products. The program’s mission is: to empower every milestone launch of innovative medical products.

Scan the QR code below to contact the assistant and schedule a live stream.

(If already added, please proactively ask the assistant)